ArticleCell communication and signaling : CCS2025

GALNT3 is a novel target driving lymphomagenesis via O-glycosylation of FGFR2.

Ruixin Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.